ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INDV Indivior Plc

987.00
25.50 (2.65%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  25.50 2.65% 987.00 994.50 1,004.00 1,013.00 958.00 1,001.00 973,842 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.09B 2M 0.0147 673.47 1.31B
Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 961.50p. Over the last year, Indivior shares have traded in a share price range of 660.00p to 1,927.00p.

Indivior currently has 136,011,398 shares in issue. The market capitalisation of Indivior is £1.31 billion. Indivior has a price to earnings ratio (PE ratio) of 673.47.

Indivior Share Discussion Threads

Showing 4476 to 4498 of 4625 messages
Chat Pages: 185  184  183  182  181  180  179  178  177  176  175  174  Older
DateSubjectAuthorDiscuss
09/7/2024
09:31
I think the lesson here is not to dabble in drugs.
casholaa
09/7/2024
09:22
the company claims that these are just temporary set backs
dealy
09/7/2024
09:22
I wonder were the dust will settle though, you’d think the buybacks would be hammered now if it’s classed as cheap
ricky46
09/7/2024
09:18
Main product sales below forecasts.
Secondary product which in the medium term was going to compensate for lower sales in the primary product now discontinued.
Costs associated with the above.
Litigation settled for an action they thought they would win.
Ongoing multiple litigations.
Potential litigation around Nasdaq listing (guaranteed I would think bearing in mind how close this statement is to the listing date).
What's there to like...?

elsa7878
09/7/2024
09:17
I have re-read the update. It looks like the management are realistic and proactive. This is an over reaction
dealy
09/7/2024
09:16
The directors selling at 1700 was always a concern for me.. lost and out here. Gla
swinsco
09/7/2024
08:53
So on the 23/5 they reconfirm guidance, that was so they got the Nasdaq listing away as smooth as possible, then the share price drifts on a leaky ship, then 7 weeks later they drop all this news, terrible untrustworthy management in my opinion glad I sold out on the drift down, wish everyone the best of luck
ricky46
09/7/2024
08:53
Still some big profit targets. Given this was trading at 1800 recently this looks overdone?
gotabsirius
09/7/2024
08:40
well, if the US listing was worth it or not , we will see today
dealy
09/7/2024
08:29
All that money I had is now pretty much gone. I hope that the cmpany takes to the opportunity to buy back as many shares as it can at these prices.
casholaa
09/7/2024
08:24
the company was buying its own shares even yesterday !!!!
dealy
09/7/2024
08:13
it's down 50% over the last few weeks. is this bad news not fully priced in now?
dealy
09/7/2024
08:09
Thought it would be worse to be fair. Horrendous update.
swinsco
09/7/2024
07:33
Ouch Condolences
scepticalinvestor
09/7/2024
07:32
Leaky ship
ricky46
09/7/2024
07:29
Now we know why it's been going down.
swinsco
09/7/2024
07:29
Not looking forward to the opening price read this morning.
A massive profit warning and Perseris discontinuation is going to keep shares weighed down.

hunter154
09/7/2024
07:16
Richmond, VA, July 9, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is:

· Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-term SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE; At the mid-point, the Group continues to expect strong YOY NR growth for SUBLOCADE of 25% and YOY adjusted operating income growth of 12% in FY 2024;

· Reiterating its medium-term financial outlook for double-digit NR growth and operating margin expansion, based on its confidence in achieving its intermediate and peak NR goals for SUBLOCADE as well as peak NR expectations for OPVEE;

· Discontinuing sales and marketing for PERSERIS due to expected adverse impacts from increased payor management of the category that crystalized in Q2 and that are expected to make the product no longer financially viable; and,

· Reaching a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases to resolve the litigation for $85m.

la forge
08/7/2024
12:38
They want to make their profit too. They can't do that without the share price taking a short term hit.
casholaa
08/7/2024
12:27
Yanks waking up.. down it goes. lol.
swinsco
06/7/2024
17:48
[...]

www.marketbeat.com/instant-alerts/nasdaq-indv-analyst-earnings-estimates-2024-07-02/

the grumpy old men
06/7/2024
14:42
Half year figures due within weeks according to my calculations . Whether that changes anything is another thing!
gregmorg
05/7/2024
14:39
Nasdaq must open... down it goes. Haha.
swinsco
Chat Pages: 185  184  183  182  181  180  179  178  177  176  175  174  Older

Your Recent History

Delayed Upgrade Clock